Day: December 10, 2025

SEOUL, South Korea and SHENZHEN, China and WILMINGTON, N.C., Dec. 10, 2025 (GLOBE NEWSWIRE) — MBAK Energy Solutions, Inc. (OTC:MBAK) has begun delivering on the $65,000,000 USD in production orders booked for 2026. Deliveries include against the BESS order for the Indian power grid, delivery of electric two and three-wheeler personal transports, and battery cells for data center power facilities. The BESS contract directly supports Indian efforts to increase national energy production capacity through renewable sources of electricity generation and storage. The company continues to field enquiries from power providers and commercial users across the region, and into North America. Demand for the company’s mobility products, specifically electric two wheelers for Europe, India, and Africa remains strong due to the company’s record...

KISSIMMEE, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) — ECD Automotive Design is proud to announce its support of Victor — the young enthusiast behind the “Little Blue Truck” build at Genesis Overland — in the transformation of his vintage Series Land Rover into a fully outfitted overland vehicle and they’re hoping to inspire more feel good moments this holiday season. Images of Victor and His Visit to the Rover Dome Video from ECD X Little Blue Truck and Victor’s Visit to the Rover Dome In September 2025, ECD’s long-term Marketing Manager, Dia Stewart, learned about Victor’s story after scrolling the company feed on Instagram, and Victor’s story immediately inspired her to help The Little Blue Truck journey. “This is solely about his journey,” Dia Stewart, Marketing Manager for ECD. “I immediately dm’d his father, Norman, asking...

MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present at the Oppenheimer Movers in Rare Disease Summit taking place at the Sofitel New York on Thursday, December 11, 2025. “For the second year in a row, we will join leaders advancing groundbreaking discoveries for rare disease at this significant meeting,” said Dr. Musunuri. “I look forward to sharing more about Ocugen’s novel modifier gene therapy platform with a gene-agnostic approach that has the potential to treat the entire disease and in turn large patient populations—in both rare and age-related blindness diseases.” Details regarding the fireside chat are as follows:Title:...

VANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) — via IBN — Branded Legacy, Inc. (OTC:BLEG) (“the Company”) today announced a comprehensive restructuring and change of control following the acquisition of the controlling interest by shareholder Dr. Jamie Forrest, PhD, MPH. Dr. Forrest, a shareholder of Branded Legacy, became increasingly dissatisfied with the Company’s direction, repeated failure to execute on announced plans, and the deteriorating financial condition of multiple subsidiaries. Rather than remain a passive investor, Dr. Forrest reached out directly to the existing control group, negotiated, and successfully purchased the entire control block, enabling an immediate and complete overhaul. Total Clean Break from the Past Effective immediately: All legacy subsidiaries have been fully...

COCONUT CREEK, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) — Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC” or the “Company”), a leading lessor of commercial jet engines, announced today that its wholly-owned subsidiary, Willis Engine Structured Trust IX (“WEST”), proposes to offer $337,400,000 in aggregate principal amount of Series A Fixed Rate Notes (the “Initial Series A Notes”) and $55,500,000 in aggregate principal amount of Series B Fixed Rate Notes (the “Initial Series B Notes” and, together with the Initial Series A Notes, the “Initial Notes”). The Notes will be secured by, among other things, WEST’s direct and indirect interests in a portfolio of 47 aircraft engines and 2 airframes, which WEST will acquire from WLFC or its other subsidiaries pursuant to an asset purchase agreement. The net proceeds of the Notes will...

Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults SCOTTSDALE, Ariz., Dec. 10, 2025 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that results from the...

Martela Corporation, inside information, 10.12.2025, at 15:30 The development of revenue and order intake has been weaker than expected during the current quarter on Martela’s key market areas. The margin development on projects and deliveries has continued to be positive in the second half of the year, but the margin levels have developed slightly below previous expectations. Due to these reasons, Martela is lowering its full-year profit forecast. New guidance for 2025: Martela Group’s full-year 2025 revenue is estimated to reach EUR 91-93 million in 2025 (EUR 86.7 million in 2024). The operating result is estimated to be negative and the operating loss is estimated to be at the level of EUR 1.1-2.3 million (operating loss in 2024 was EUR 6.5 million). Previous guidance for 2025: Martela anticipates its revenue to increase...

THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The paper, titled “Acyl-CoA Synthetase 5 knockout and inhibitors protect against diet-induced obesity in mice by activating the ileal brake,” was published online in the Journal of the Endocrine Society. ACSL5 is an enzyme encoded by the Acsl5 gene that plays a vital role in lipid metabolism and is the target of LX9851, the Company’s investigational non-incretin, oral, small molecule ACSL5 inhibitor. Animal model data showed that mice genetically modified to lack the ACSL5 gene exhibited favorable metabolic characteristics, including reduced body fat and conserved lean body mass. In March...

TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is excited to announce that it has completed release testing of its first Australian-made batch of LaNeo™ MDMA 40mg capsules. “PharmAla is pleased to have completed this first batch of material of Australian-made materials in partnership with our colleagues at Cortexa. This material will continue to drive progress in the Australian market, as well as our ongoing operations globally,” said Farnoud Kazemzadeh, COO, PharmAla Biotech. “However, we are all the more excited to move forward into a very active production schedule for 2026 – including the development...